Our Pricing

Side Effects of Saxenda: What UK Patients Need to Know

Published on: June 03, 2026

Understanding the side effects of Saxenda is essential for anyone considering this liraglutide-based weight loss treatment in the UK. As a GLP-1 receptor agonist prescribed for chronic weight management, Saxenda is clinically proven to support weight loss, but like all prescription medicines, it can cause adverse effects that vary in severity and frequency [1]. Most patients experience mild to moderate gastrointestinal symptoms during the initial titration phase, though these typically improve as the body adjusts to the medication.

Common Side Effects of Saxenda in Clinical Trials

The most frequently reported side effects of Saxenda involve the digestive system, reflecting its mechanism of action on GLP-1 receptors in the gut and brain [1]. In the pivotal SCALE clinical trial programme involving over 5,000 participants, nausea was the most common adverse effect, reported by approximately 39% of patients taking liraglutide 3.0 mg compared to 14% on placebo [2]. Diarrhoea affected around 21% of Saxenda users, whilst constipation occurred in approximately 20% of patients during the study period.

Vomiting, dyspepsia (indigestion), and abdominal pain were also commonly observed, though these gastrointestinal side effects typically peaked during dose escalation and diminished over subsequent weeks [2]. The structured titration schedule—starting at 0.6 mg daily and increasing by 0.6 mg weekly increments—is specifically designed to minimise these effects and improve tolerability. Most patients who experience nausea find it manageable with dietary adjustments, such as eating smaller, more frequent meals and avoiding high-fat foods.

Injection site reactions represent another category of common side effects of Saxenda, with approximately 14% of trial participants reporting mild redness, itching, or bruising at the injection site [1]. These localised reactions are generally transient and resolve without intervention. Rotating injection sites between the abdomen, thigh, and upper arm—as recommended in the patient information leaflet—can significantly reduce the frequency and severity of these reactions.

Serious Side Effects of Saxenda Requiring Medical Attention

Whilst most side effects of Saxenda are mild and self-limiting, certain serious adverse events require immediate medical evaluation. Acute pancreatitis, though rare, has been reported in patients using GLP-1 receptor agonists including liraglutide [3]. Symptoms include severe, persistent abdominal pain that may radiate to the back, often accompanied by nausea and vomiting. If you experience these symptoms, discontinue Saxenda immediately and contact your GP or NHS 111 for urgent assessment.

Gallbladder disorders, including cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation), occurred more frequently in Saxenda-treated patients compared to placebo in clinical trials [2]. Rapid weight loss itself is a known risk factor for gallstone formation, making it difficult to separate the medication's direct contribution from the weight loss effect. Symptoms such as sudden severe pain in the upper right abdomen, yellowing of the skin or eyes, or fever warrant immediate medical attention.

Hypoglycaemia (low blood sugar) is uncommon in patients using Saxenda alone, but the risk increases substantially when combined with other diabetes medications, particularly insulin or sulphonylureas [3]. Signs include dizziness, sweating, confusion, rapid heartbeat, and extreme hunger. Patients with type 2 diabetes require careful monitoring and potential dose adjustments of concurrent medications when starting Saxenda. Allergic reactions, whilst rare, can range from mild rash to severe anaphylaxis; any difficulty breathing, facial swelling, or widespread urticaria requires emergency medical care.

Thyroid Concerns and Saxenda Use

Liraglutide carries a boxed warning regarding thyroid C-cell tumours based on rodent studies, though no causal relationship has been established in humans [3]. Saxenda is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). During your clinical assessment at Cured Pharmacy, our UK-registered prescribers carefully screen for these contraindications to ensure safe prescribing. Patients should report any neck lumps, persistent hoarseness, difficulty swallowing, or shortness of breath to their healthcare provider promptly.

Managing the Side Effects of Saxenda: Practical Strategies

Effective management of the side effects of Saxenda can significantly improve treatment adherence and overall experience. For gastrointestinal symptoms, dietary modifications prove highly effective: consuming smaller portions more frequently throughout the day reduces stomach distension and nausea [4]. Avoiding fatty, fried, or heavily spiced foods during the initial weeks helps minimise digestive upset, as does staying well-hydrated with water and clear fluids.

Taking Saxenda at a consistent time each day—many patients prefer evening administration—can help the body establish a predictable rhythm and may reduce daytime nausea. If nausea persists despite these measures, ginger supplements or anti-emetic medications prescribed by your GP may provide relief. Never increase your Saxenda dose until gastrointestinal symptoms from the current dose have substantially resolved; the weekly titration schedule exists precisely to allow your body time to adapt.

For injection site reactions, proper technique is paramount. Allow the Saxenda pen to reach room temperature before injecting, clean the site with an alcohol wipe, and use a fresh needle for each injection. Rotate sites systematically rather than using the same location repeatedly. If bruising occurs, applying gentle pressure (without rubbing) immediately after injection can minimise discolouration. Most injection-related side effects of Saxenda improve markedly as patients become more confident with the technique.

When to Contact Your Prescriber

Certain symptoms warrant direct communication with your prescriber or GP. Persistent vomiting that prevents adequate fluid intake risks dehydration and electrolyte imbalance. Severe or worsening abdominal pain, particularly if accompanied by fever, requires same-day medical evaluation to rule out pancreatitis or gallbladder complications [3]. Changes in heart rate, especially a sustained resting heart rate increase of more than 10-15 beats per minute, should be reported, as tachycardia has been observed in some Saxenda users. At Cured Pharmacy, our clinical team remains available to address concerns and adjust treatment plans as needed throughout your weight loss journey.

Comparing Side Effects of Saxenda to Other Weight Loss Treatments

When evaluating the side effects of Saxenda against alternative weight loss medications available in the UK, the gastrointestinal symptom profile differs notably between drug classes. Orlistat (Xenical, Alli) causes fat malabsorption, leading to oily stools, faecal urgency, and anal leakage—side effects mechanistically distinct from Saxenda's GLP-1-mediated nausea and delayed gastric emptying [4]. Patients who cannot tolerate fatty stool changes with orlistat may find Saxenda's nausea more manageable, and vice versa.

Newer GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Mounjaro) share a similar side effect spectrum with Saxenda, as they act on the same receptor pathways. However, dosing frequency differs: Saxenda requires daily subcutaneous injection, whilst Wegovy and Mounjaro are administered weekly, potentially offering convenience advantages [5]. Gastrointestinal side effects occur with all three medications, though individual tolerance varies. Some patients who experience intolerable nausea on one GLP-1 agonist may tolerate another better, though switching should only occur under medical supervision.

The side effects of Saxenda must be weighed against its proven efficacy: in the SCALE Obesity and Prediabetes trial, patients lost an average of 8% of their initial body weight over 56 weeks compared to 2.6% with placebo [2]. This clinically meaningful weight reduction, combined with improvements in cardiovascular risk factors, often justifies tolerating transient gastrointestinal symptoms for many patients. Your prescriber will help determine whether Saxenda's benefit-risk profile aligns with your individual health status, weight loss goals, and tolerance for potential adverse effects.

Long-Term Side Effects of Saxenda: What Research Shows

Long-term safety data for the side effects of Saxenda extends beyond three years from extension phases of the SCALE clinical trial programme [2]. Gastrointestinal adverse effects, whilst common during initial titration, typically diminish substantially after the first 12-16 weeks of treatment. In the three-year SCALE Obesity and Prediabetes study, discontinuation rates due to adverse events were highest in the first six months and declined thereafter, suggesting improved tolerability with continued use.

Cardiovascular safety represents a critical consideration for any obesity medication. The LEADER trial, which studied liraglutide 1.8 mg in patients with type 2 diabetes, demonstrated cardiovascular safety and even suggested potential benefit, though this was at a lower dose than the 3.0 mg used for weight management [5]. Heart rate increases of 2-3 beats per minute above baseline were observed and persisted throughout treatment, though this modest elevation did not translate to increased cardiovascular events in clinical trials. Patients with pre-existing cardiovascular conditions require individualised risk assessment before starting Saxenda.

Bone health, nutrient absorption, and metabolic parameters have been monitored in long-term Saxenda users without signals of significant concern [4]. Unlike some historical weight loss medications, liraglutide does not appear to cause valvular heart disease or pulmonary hypertension. Ongoing post-marketing surveillance by the MHRA continues to monitor for rare or delayed adverse effects not apparent in clinical trials. At Cured Pharmacy, we provide Saxenda at £48.00 per pen, with £20 off your first order using code Weightlossnew, ensuring UK patients access this clinically-proven treatment at the cheapest UK price whilst maintaining rigorous safety standards through our online prescriber assessments.

Renal and Hepatic Considerations

Patients with kidney or liver impairment require special consideration regarding the side effects of Saxenda. Severe gastrointestinal symptoms leading to dehydration can precipitate acute kidney injury, particularly in patients with pre-existing renal disease [3]. Dose adjustments are not routinely required for mild to moderate renal or hepatic impairment, but clinical monitoring is essential. Saxenda is not recommended for patients with severe renal impairment (eGFR <30 mL/min/1.73m²) or end-stage renal disease due to limited safety data in these populations.

Who Should Avoid Saxenda Due to Side Effect Risks

Certain patient populations face elevated risks from the side effects of Saxenda and should not use this medication. Absolute contraindications include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, previous serious hypersensitivity to liraglutide or any excipients, and pregnancy or breastfeeding [1]. Women of childbearing potential should use effective contraception during treatment and discontinue Saxenda at least two months before planned conception.

Patients with inflammatory bowel disease or diabetic gastroparesis may experience worsening gastrointestinal symptoms due to Saxenda's effect on gastric emptying [3]. Those with a history of pancreatitis face increased risk of recurrence, though the causal relationship remains debated in medical literature. Severe, unstable cardiovascular disease warrants caution, as does concurrent use of other GLP-1 receptor agonists or DPP-4 inhibitors. Age under 18 years represents another contraindication, as safety and efficacy have not been established in paediatric populations.

During the online clinical assessment at Cured Pharmacy, our UK-registered prescribers systematically screen for these contraindications and relative precautions. Patients taking medications that slow gastric emptying, such as opioid analgesics, may require additional monitoring due to potential interaction effects. Mental health history, particularly depression with suicidal ideation, requires careful consideration, as mood changes have been reported in some patients using weight loss medications [4]. Our prescribers balance the potential benefits of Saxenda against individual risk factors to ensure safe, appropriate prescribing aligned with MHRA guidelines and NICE recommendations for obesity management.

Scientific References

1. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. [accessed 13 August 2026]
2. Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V., Hale, P. M., & Aronne, L. (2013). Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International Journal of Obesity, 37(11), 1443-1451. [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2021). Saxenda 6 mg/ml solution for injection in pre-filled pen: Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/2313/smpc [accessed 13 August 2026]
4. Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., ... & Mignot, E. (2016). Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. International Journal of Obesity, 40(8), 1310-1319. [accessed 13 August 2026]
5. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., ... & Poulter, N. R. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322. [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.